UBS Asset Management Americas Inc. Sells 60,655 Shares of Opko Health Inc. (NASDAQ:OPK)

UBS Asset Management Americas Inc. lowered its holdings in shares of Opko Health Inc. (NASDAQ:OPK) by 22.0% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 214,991 shares of the biotechnology company’s stock after selling 60,655 shares during the period. UBS Asset Management Americas Inc.’s holdings in Opko Health were worth $525,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in OPK. Eqis Capital Management Inc. acquired a new position in shares of Opko Health in the 2nd quarter worth $33,000. B. Riley Wealth Management Inc. acquired a new position in shares of Opko Health in the 1st quarter worth $39,000. Sawtooth Solutions LLC acquired a new position in shares of Opko Health in the 2nd quarter worth $45,000. Kings Point Capital Management acquired a new position in shares of Opko Health in the 2nd quarter worth $45,000. Finally, GABELLI & Co INVESTMENT ADVISERS INC. grew its holdings in shares of Opko Health by 100.0% in the 2nd quarter. GABELLI & Co INVESTMENT ADVISERS INC. now owns 20,000 shares of the biotechnology company’s stock worth $49,000 after acquiring an additional 10,000 shares during the last quarter. 24.54% of the stock is currently owned by hedge funds and other institutional investors.

In other Opko Health news, Vice Chairman Jane Ph D. Hsiao acquired 400,000 shares of Opko Health stock in a transaction dated Friday, October 25th. The stock was bought at an average cost of $1.50 per share, for a total transaction of $600,000.00. Following the purchase, the insider now directly owns 24,475,147 shares in the company, valued at approximately $36,712,720.50. The purchase was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Phillip Md Et Al Frost acquired 350,000 shares of Opko Health stock in a transaction dated Wednesday, November 6th. The shares were acquired at an average price of $1.49 per share, with a total value of $521,500.00. Following the completion of the purchase, the chief executive officer now owns 3,068,951 shares in the company, valued at $4,572,736.99. The disclosure for this purchase can be found here. Over the last 90 days, insiders have bought 3,040,000 shares of company stock valued at $4,545,750. Company insiders own 42.25% of the company’s stock.

OPK has been the topic of a number of recent research reports. Zacks Investment Research upgraded Opko Health from a “hold” rating to a “buy” rating and set a $2.00 target price on the stock in a report on Friday, October 18th. BidaskClub cut Opko Health from a “hold” rating to a “sell” rating in a research report on Tuesday, October 29th. ValuEngine raised Opko Health from a “sell” rating to a “hold” rating in a research report on Thursday, August 1st. Finally, Barrington Research reaffirmed a “buy” rating and issued a $4.00 target price on shares of Opko Health in a research report on Thursday, September 12th.

Shares of Opko Health stock traded down $0.04 during midday trading on Friday, hitting $1.47. The company’s stock had a trading volume of 7,800,700 shares, compared to its average volume of 4,798,398. The stock has a 50-day simple moving average of $1.89 and a 200-day simple moving average of $2.01. The firm has a market capitalization of $960.34 million, a P/E ratio of -5.88 and a beta of 2.17. The company has a quick ratio of 1.04, a current ratio of 1.21 and a debt-to-equity ratio of 0.13. Opko Health Inc. has a 1-year low of $1.33 and a 1-year high of $3.93.

Opko Health (NASDAQ:OPK) last released its earnings results on Tuesday, November 5th. The biotechnology company reported ($0.11) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.09) by ($0.02). Opko Health had a negative return on equity of 14.19% and a negative net margin of 30.98%. The firm had revenue of $228.80 million for the quarter, compared to the consensus estimate of $225.40 million. During the same quarter last year, the company posted ($0.05) EPS. Opko Health’s revenue for the quarter was down 8.4% on a year-over-year basis. As a group, sell-side analysts predict that Opko Health Inc. will post -0.41 earnings per share for the current year.

Opko Health Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals business in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories, a clinical laboratory that offers laboratory testing services.

Read More: What is Forex?

Institutional Ownership by Quarter for Opko Health (NASDAQ:OPK)

Receive News & Ratings for Opko Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health and related companies with MarketBeat.com's FREE daily email newsletter.